

VIP and PACAP receptors in GtoPdb v.2023.1

Jan Fahrenkrug¹, Edward J. Goetzl², Illana Gozes³, Anthony Harmar⁴, Marc Laburthe⁵, Victor May⁶, Joseph R. Pisegna⁷, Sami I. Said⁸, David Vaudry⁹, Hubert Vaudry⁹ and James A. Waschek⁷

1. University of Copenhagen, Denmark
2. University of California San Francisco, USA
3. Tel Aviv University, Israel
4. University of Edinburgh, UK
5. INSERM, France
6. University of Vermont College of Medicine, USA
7. University of California Los Angeles, USA
8. State University of New York at Stony Brook, USA
9. Normandy University, France

Abstract

Vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase-activating peptide (PACAP) receptors (**nomenclature as agreed by the NC-IUPHAR Subcommittee on Vasoactive Intestinal Peptide Receptors [65, 66]**) are activated by the endogenous peptides **VIP**, **PACAP-38**, **PACAP-27**, peptide histidine isoleucineamide (**PHI**), peptide histidine methionineamide (**PHM**) and peptide histidine valine (**PHV**). VPAC₁ and VPAC₂ receptors display comparable affinity for the PACAP peptides, **PACAP-27** and **PACAP-38**, and **VIP**, whereas **PACAP-27** and **PACAP-38** are >100 fold more potent than **VIP** as agonists of most isoforms of the PAC₁ receptor. However, one splice variant of the human PAC₁ receptor has been reported to respond to **PACAP-38**, **PACAP-27** and **VIP** with comparable affinity [30]. **PG 99-465** [117] has been used as a selective VPAC₂ receptor antagonist in a number of physiological studies, but has been reported to have significant activity at VPAC₁ and PAC₁ receptors [36]. The selective PAC₁ receptor agonist **maxadilan**, was extracted from the salivary glands of sand flies (*Lutzomyia longipalpis*) and has no sequence homology to **VIP** or the PACAP peptides [118]. Two deletion variants of **maxadilan**, **M65** [183] and **Max.d.4** [119] have been reported to be PAC₁ receptor antagonists, but these peptides have not been extensively characterised.

Contents

This is a citation summary for VIP and PACAP receptors in the [Guide to Pharmacology](#) database (GtoPdb). It exists purely as an adjunct to the database to facilitate the recognition of citations to and from the database by citation analyzers. Readers will almost certainly want to visit the relevant sections of the database which are given here under database links.

[GtoPdb](#) is an expert-driven guide to pharmacological targets and the substances that act on them. GtoPdb is a reference work which is most usefully represented as an on-line database. As in any publication this work should be appropriately cited, and the papers it cites should also be recognized. This document provides a citation for the relevant parts of the database, and also provides a reference list for the research cited by those parts. For further details see [18].

Please note that the database version for the citations given in GtoPdb are to the most recent preceding version in which the family or its subfamilies and targets were substantially changed. The links below are to

the current version. If you need to consult the cited version, rather than the most recent version, please contact the GtoPdb curators.

Database links

VIP and PACAP receptors

<https://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=67>

Introduction to VIP and PACAP receptors

<https://www.guidetopharmacology.org/GRAC/FamilyIntroductionForward?familyId=67>

Receptors

PAC₁ receptor

<https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=370>

VPAC₁ receptor

<https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=371>

VPAC₂ receptor

<https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=372>

References

1. Abad C, Jayaram B, Becquet L, Wang Y, O'Dorisio MS, Waschek JA and Tan YV. (2016) VPAC1 receptor (Vipr1)-deficient mice exhibit ameliorated experimental autoimmune encephalomyelitis, with specific deficits in the effector stage. *J Neuroinflammation* **13**: 169 [PMID:27357191]
2. Abad C, Martinez C, Juarranz MG, Arranz A, Leceta J, Delgado M and Gomariz RP. (2003) Therapeutic effects of vasoactive intestinal peptide in the trinitrobenzene sulfonic acid mice model of Crohn's disease. *Gastroenterology* **124**: 961-971 [PMID:12671893]
3. Abad C, Tan YV, Lopez R, Nobuta H, Dong H, Phan P, Feng JM, Campagnoni AT and Waschek JA. (2010) Vasoactive intestinal peptide loss leads to impaired CNS parenchymal T-cell infiltration and resistance to experimental autoimmune encephalomyelitis. *Proc Natl Acad Sci USA* **107**: 19555-60 [PMID:20978211]
4. Adamou JE, Aiyar N, Van Horn S and Elshourbagy NA. (1995) Cloning and functional characterization of the human vasoactive intestinal peptide (VIP)-2 receptor. *Biochem Biophys Res Commun* **209**: 385-92 [PMID:7733904]
5. Aino H, Hashimoto H, Ogawa N, Nishino A, Yamamoto K, Nogi H, Nagata S and Baba A. (1995) Structure of the gene encoding the mouse pituitary adenylate cyclase-activating polypeptide receptor. *Gene* **164**: 301-4 [PMID:7590347]
6. Aoki Y, Iwasaki Y, Katahira M, Oiso Y and Saito H. (1997) Regulation of the rat proopiomelanocortin gene expression in AtT-20 cells. II: Effects of the pituitary adenylate cyclase-activating polypeptide and vasoactive intestinal polypeptide. *Endocrinology* **138**: 1930-4 [PMID:9112389]
7. Arimura A and Shioda S. (1995) Pituitary adenylate cyclase activating polypeptide (PACAP) and its receptors: neuroendocrine and endocrine interaction. *Front Neuroendocrinol* **16**: 53-88 [PMID:7768322]
8. Asnicar MA, Köster A, Heiman ML, Tinsley F, Smith DP, Galbreath E, Fox N, Ma YL, Blum WF and Hsiung HM. (2002) Vasoactive intestinal polypeptide/pituitary adenylate cyclase-activating peptide receptor 2 deficiency in mice results in growth retardation and increased basal metabolic rate. *Endocrinology* **143**: 3994-4006 [PMID:12239111]
9. Aton SJ, Colwell CS, Harmar AJ, Waschek J and Herzog ED. (2005) Vasoactive intestinal polypeptide mediates circadian rhythmicity and synchrony in mammalian clock neurons. *Nat Neurosci* **8**: 476-83 [PMID:15750589]
10. Basille M, Gonzalez BJ, Fournier A and Vaudry H. (1994) Ontogeny of pituitary adenylate cyclase-activating polypeptide (PACAP) receptors in the rat cerebellum: a quantitative autoradiographic study. *Brain Res Dev Brain Res* **82**: 81-9 [PMID:7842522]
11. Basille M, Gonzalez BJ, Leroux P, Jeandel L, Fournier A and Vaudry H. (1993) Localization and characterization of PACAP receptors in the rat cerebellum during development: evidence for a stimulatory effect of PACAP on immature cerebellar granule cells. *Neuroscience* **57**: 329-38 [PMID:8115042]
12. Basille M, Vaudry D, Coulouarn Y, Jegou S, Lihmann I, Fournier A, Vaudry H and Gonzalez B. (2000)

- Comparative distribution of pituitary adenylate cyclase-activating polypeptide (PACAP) binding sites and PACAP receptor mRNAs in the rat brain during development. *J Comp Neurol* **425**: 495-509 [PMID:10975876]
13. Bechtold DA, Brown TM, Luckman SM and Piggins HD. (2008) Metabolic rhythm abnormalities in mice lacking VIP-VPAC2 signaling. *Am J Physiol Regul Integr Comp Physiol* **294**: R344-51 [PMID:18032467]
 14. Beebe X, Darczak D, Davis-Taber RA, Uchic ME, Scott VE, Jarvis MF and Stewart AO. (2008) Discovery and SAR of hydrazide antagonists of the pituitary adenylate cyclase-activating polypeptide (PACAP) receptor type 1 (PAC1-R). *Bioorg Med Chem Lett* **18**: 2162-6 [PMID:18272364]
 15. Bergström AL, Hannibal J, Hindersson P and Fahrenkrug J. (2003) Light-induced phase shift in the Syrian hamster (*Mesocricetus auratus*) is attenuated by the PACAP receptor antagonist PACAP6-38 or PACAP immunoneutralization. *Eur J Neurosci* **18**: 2552-62 [PMID:14622156]
 16. Besson J, Sarrieau A, Vial M, Marie JC, Rosselin G and Rostene W. (1986) Characterization and autoradiographic distribution of vasoactive intestinal peptide binding sites in the rat central nervous system. *Brain Res* **398**: 329-36 [PMID:3801907]
 17. Brenneman DE and Eiden LE. (1986) Vasoactive intestinal peptide and electrical activity influence neuronal survival. *Proc Natl Acad Sci USA* **83**: 1159-62 [PMID:3456568]
 18. Buneman P, Christie G, Davies JA, Dimitrellou R, Harding SD, Pawson AJ, Sharman JL and Wu Y. (2020) Why data citation isn't working, and what to do about it *Database* **2020** [PMID:32367113]
 19. Cai Y, Xin X, Yamada T, Muramatsu Y, Szpirer C and Matsumoto K. (1995) Assignments of the genes for rat pituitary adenylate cyclase activating polypeptide (Adcyap1) and its receptor subtypes (Adcyap1r1, Adcyap1r2, and Adcyap1r3). *Cytogenet Cell Genet* **71**: 193-6 [PMID:7656595]
 20. Cavallaro S, Copani A, D'Agata V, Musco S, Petralia S, Ventra C, Stivala F, Travali S and Canonico PL. (1996) Pituitary adenylate cyclase activating polypeptide prevents apoptosis in cultured cerebellar granule neurons. *Mol Pharmacol* **50**: 60-6 [PMID:8700120]
 21. Christopoulos A, Christopoulos G, Morfis M, Udawela M, Laburthe M, Couvineau A, Kuwasako K, Tilakaratne N and Sexton PM. (2003) Novel receptor partners and function of receptor activity-modifying proteins. *J Biol Chem* **278**: 3293-7 [PMID:12446722]
 22. Chu A, Caldwell JS and Chen YA. (2010) Identification and characterization of a small molecule antagonist of human VPAC(2) receptor. *Mol Pharmacol* **77**: 95-101 [PMID:19854890]
 23. Ciccarelli E, Svoboda M, De Neef P, Di Paolo E, Bollen A, Dubeaux C, Vilaradaga JP, Waelbroeck M and Robberecht P. (1995) Pharmacological properties of two recombinant splice variants of the PACAP type I receptor, transfected and stably expressed in CHO cells. *Eur J Pharmacol* **288**: 259-67 [PMID:7774670]
 24. Colwell CS, Michel S, Itri J, Rodriguez W, Tam J, Lelievre V, Hu Z, Liu X and Waschek JA. (2003) Disrupted circadian rhythms in VIP- and PHI-deficient mice. *Am J Physiol Regul Integr Comp Physiol* **285**: R939-49 [PMID:12855416]
 25. Colwell CS, Michel S, Itri J, Rodriguez W, Tam J, Lelièvre V, Hu Z and Waschek JA. (2004) Selective deficits in the circadian light response in mice lacking PACAP. *Am J Physiol Regul Integr Comp Physiol* **287**: R1194-201 [PMID:15217792]
 26. Couvineau A and Laburthe M. (2012) The family B1 GPCR: structural aspects and interaction with accessory proteins. *Curr Drug Targets* **13**: 103-15 [PMID:21777182]
 27. Couvineau A, Rouyer-Fessard C, Maoret JJ, Gaudin P, Nicole P and Laburthe M. (1996) Vasoactive intestinal peptide (VIP)1 receptor. Three nonadjacent amino acids are responsible for species selectivity with respect to recognition of peptide histidine isoleucineamide. *J Biol Chem* **271**: 12795-800 [PMID:8662697]
 28. Cutler DJ, Haraura M, Reed HE, Shen S, Sheward WJ, Morrison CF, Marston HM, Harmar AJ and Piggins HD. (2003) The mouse VPAC2 receptor confers suprachiasmatic nuclei cellular rhythmicity and responsiveness to vasoactive intestinal polypeptide in vitro. *Eur J Neurosci* **17**: 197-204 [PMID:12542655]
 29. Daniel PB, Kieffer TJ, Leech CA and Habener JF. (2001) Novel alternatively spliced exon in the extracellular ligand-binding domain of the pituitary adenylate cyclase-activating polypeptide (PACAP) type 1 receptor (PAC1R) selectively increases ligand affinity and alters signal transduction coupling during spermatogenesis. *J Biol Chem* **276**: 12938-44 [PMID:11278585]
 30. Dautzenberg FM, Mevenkamp G, Wille S and Hauger RL. (1999) N-terminal splice variants of the type I PACAP receptor: isolation, characterization and ligand binding/selectivity determinants. *J Neuroendocrinol* **11**: 941-9 [PMID:10583729]
 31. Delgado M, Martinez C, Johnson MC, Gomariz RP and Ganea D. (1996) Differential expression of

- vasoactive intestinal peptide receptors 1 and 2 (VIP-R1 and VIP-R2) mRNA in murine lymphocytes. *J Neuroimmunol* **68**: 27-38 [PMID:8784257]
32. Delporte C, Poloczek P, de Neef P, Vertongen P, Ciccarelli E, Svoboda M, Herchuelz A, Winand J and Robberecht P. (1995) Pituitary adenylate cyclase activating polypeptide (PACAP) and vasoactive intestinal peptide stimulate two signaling pathways in CHO cells stably transfected with the selective type I PACAP receptor. *Mol Cell Endocrinol* **107**: 71-6 [PMID:7796937]
 33. Deng AY, Gu L, Rapp JP, Szpirer C and Szpirer J. (1994) Chromosomal assignment of 11 loci in the rat by mouse-rat somatic hybrids and linkage. *Mamm Genome* **5**: 712-6 [PMID:7873882]
 34. Dickinson T and Fleetwood-Walker SM. (1999) VIP and PACAP: very important in pain? *Trends Pharmacol Sci* **20**: 324-9 [PMID:10431211]
 35. Dickinson T, Mitchell R, Robberecht P and Fleetwood-Walker SM. (1999) The role of VIP/PACAP receptor subtypes in spinal somatosensory processing in rats with an experimental peripheral mononeuropathy. *Neuropharmacology* **38**: 167-80 [PMID:10193908]
 36. Dickson L, Aramori I, McCulloch J, Sharkey J and Finlayson K. (2006) A systematic comparison of intracellular cyclic AMP and calcium signalling highlights complexities in human VPAC/PAC receptor pharmacology. *Neuropharmacology* **51**: 1086-98 [PMID:16930633]
 37. Fabricius D, Karacay B, Shutt D, Leverich W, Schafer B, Takle E, Thedens D, Khanna G, Raikwar S and Yang B *et al.* (2011) Characterization of intestinal and pancreatic dysfunction in VPAC1-null mutant mouse. *Pancreas* **40**: 861-71 [PMID:21697765]
 38. Fahrenkrug J and Hannibal J. (2011) Localisation of the neuropeptide PACAP and its receptors in the rat parathyroid and thyroid glands. *Gen Comp Endocrinol* **171**: 105-13 [PMID:21176780]
 39. Falluel-Morel A, Vaudry D, Aubert N, Galas L, Benard M, Basille M, Fontaine M, Fournier A, Vaudry H and Gonzalez BJ. (2005) Pituitary adenylate cyclase-activating polypeptide prevents the effects of ceramides on migration, neurite outgrowth, and cytoskeleton remodeling. *Proc Natl Acad Sci USA* **102**: 2637-42 [PMID:15695581]
 40. Foord SM, Bonner TI, Neubig RR, Rosser EM, Pin JP, Davenport AP, Spedding M and Harmar AJ. (2005) International Union of Pharmacology. XLVI. G protein-coupled receptor list. *Pharmacol Rev* **57**: 279-88 [PMID:15914470]
 41. Gaudin P, Couvineau A, Maoret JJ, Rouyer-Fessard C and Laburthe M. (1996) Stable expression of the recombinant human VIP1 receptor in clonal Chinese hamster ovary cells: pharmacological, functional and molecular properties. *Eur J Pharmacol* **302**: 207-14 [PMID:8791009]
 42. Ghatei MA, Takahashi K, Suzuki Y, Gardiner J, Jones PM and Bloom SR. (1993) Distribution, molecular characterization of pituitary adenylate cyclase-activating polypeptide and its precursor encoding messenger RNA in human and rat tissues. *J Endocrinol* **136**: 159-66 [PMID:8094091]
 43. Goetzl EJ, Voice JK, Shen S, Dorsam G, Kong Y, West KM, Morrison CF and Harmar AJ. (2001) Enhanced delayed-type hypersensitivity and diminished immediate-type hypersensitivity in mice lacking the inducible VPAC(2) receptor for vasoactive intestinal peptide. *Proc Natl Acad Sci USA* **98**: 13854-9 [PMID:11698667]
 44. Gomariz RP, Juarranz Y, Abad C, Arranz A, Leceta J and Martinez C. (2006) VIP-PACAP system in immunity: new insights for multitarget therapy. *Ann N Y Acad Sci* **1070**: 51-74 [PMID:16888149]
 45. Gonzalez BJ, Basille M, Vaudry D, Fournier A and Vaudry H. (1997) Pituitary adenylate cyclase-activating polypeptide promotes cell survival and neurite outgrowth in rat cerebellar neuroblasts. *Neuroscience* **78**: 419-30 [PMID:9145799]
 46. Gonzalez-Rey E, Fernandez-Martin A, Chorny A, Martin J, Pozo D, Ganea D and Delgado M. (2006) Therapeutic effect of vasoactive intestinal peptide on experimental autoimmune encephalomyelitis: down-regulation of inflammatory and autoimmune responses. *Am J Pathol* **168**: 1179-88 [PMID:16565493]
 47. Gourlet P, De Neef P, Cnudde J, Waelbroeck M and Robberecht P. (1997) In vitro properties of a high affinity selective antagonist of the VIP1 receptor. *Peptides* **18**: 1555-60 [PMID:9437716]
 48. Gourlet P, Rathé J, De Neef P, Cnudde J, Vandermeers-Piret MC, Waelbroeck M and Robberecht P. (1998) Interaction of lipophilic VIP derivatives with recombinant VIP1/PACAP and VIP2/PACAP receptors. *Eur J Pharmacol* **354**: 105-11 [PMID:9726637]
 49. Gourlet P, Vandermeers A, Van Rampelbergh J, De Neef P, Cnudde J, Waelbroeck M and Robberecht P. (1998) Analogues of VIP, helodermin, and PACAP discriminate between rat and human VIP1 and VIP2 receptors. *Ann N Y Acad Sci* **865**: 247-52 [PMID:9928018]

50. Gourlet P, Vandermeers A, Vertongen P, Rathe J, De Neef P, Cnudde J, Waelbroeck M and Robberecht P. (1997) Development of high affinity selective VIP1 receptor agonists. *Peptides* **18**: 1539-45 [PMID:9437714]
51. Gourlet P, Vertongen P, Vandermeers A, Vandermeers-Piret MC, Rathe J, De Neef P, Waelbroeck M and Robberecht P. (1997) The long-acting vasoactive intestinal polypeptide agonist RO 25-1553 is highly selective of the VIP2 receptor subclass. *Peptides* **18**: 403-8 [PMID:9145428]
52. Gozes I. (2011) NAP (davunetide) provides functional and structural neuroprotection. *Curr Pharm Des* **17**: 1040-4 [PMID:21524250]
53. Gozes I and Brenneman DE. (1989) VIP: molecular biology and neurobiological function. *Mol Neurobiol* **3**: 201-36 [PMID:2698176]
54. Grace CR, Perrin MH, DiGrucchio MR, Miller CL, Rivier JE, Vale WW and Riek R. (2004) NMR structure and peptide hormone binding site of the first extracellular domain of a type B1 G protein-coupled receptor. *Proc Natl Acad Sci USA* **101**: 12836-41 [PMID:15326300]
55. Gressens P, Besse L, Robberecht P, Gozes I, Fridkin M and Evrard P. (1999) Neuroprotection of the developing brain by systemic administration of vasoactive intestinal peptide derivatives. *J Pharmacol Exp Ther* **288**: 1207-13 [PMID:10027860]
56. Gressens P, Marret S, Hill JM, Brenneman DE, Gozes I, Fridkin M and Evrard P. (1997) Vasoactive intestinal peptide prevents excitotoxic cell death in the murine developing brain. *J Clin Invest* **100**: 390-7 [PMID:9218516]
57. Grininger C, Wang W, Oskoui KB, Voice JK and Goetzl EJ. (2004) A natural variant type II G protein-coupled receptor for vasoactive intestinal peptide with altered function. *J Biol Chem* **279**: 40259-40262 [PMID:15302876]
58. Hamelink C, Tjurmina O, Damadzic R, Young WS, Weihe E, Lee HW and Eiden LE. (2002) Pituitary adenylate cyclase-activating polypeptide is a sympathoadrenal neurotransmitter involved in catecholamine regulation and glucohomeostasis. *Proc Natl Acad Sci USA* **99**: 461-6 [PMID:11756684]
59. Hammack SE, Roman CW, Lezak KR, Kocho-Shellenberg M, Grimmig B, Falls WA, Braas K and May V. (2010) Roles for pituitary adenylate cyclase-activating peptide (PACAP) expression and signaling in the bed nucleus of the stria terminalis (BNST) in mediating the behavioral consequences of chronic stress. *J Mol Neurosci* **42**: 327-40 [PMID:20405238]
60. Hannibal J, Brabet P and Fahrenkrug J. (2008) Mice lacking the PACAP type I receptor have impaired photic entrainment and negative masking. *Am J Physiol Regul Integr Comp Physiol* **295**: R2050-8 [PMID:18922961]
61. Hannibal J, Ding JM, Chen D, Fahrenkrug J, Larsen PJ, Gillette MU and Mikkelsen JD. (1997) Pituitary adenylate cyclase-activating peptide (PACAP) in the retinohypothalamic tract: a potential daytime regulator of the biological clock. *J Neurosci* **17**: 2637-44 [PMID:9065523]
62. Hannibal J, Hsiung HM and Fahrenkrug J. (2011) Temporal phasing of locomotor activity, heart rate rhythmicity, and core body temperature is disrupted in VIP receptor 2-deficient mice. *Am J Physiol Regul Integr Comp Physiol* **300**: R519-30 [PMID:21178124]
63. Hannibal J, Jamen F, Nielsen HS, Journot L, Brabet P and Fahrenkrug J. (2001) Dissociation between light-induced phase shift of the circadian rhythm and clock gene expression in mice lacking the pituitary adenylate cyclase activating polypeptide type 1 receptor. *J Neurosci* **21**: 4883-90 [PMID:11425915]
64. Harmar AJ. (2001) Family-B G-protein-coupled receptors. *Genome Biol* **2**: REVIEWS3013 [PMID:11790261]
65. Harmar AJ, Arimura A, Gozes I, Journot L, Laburthe M, Pisegna JR, Rawlings SR, Robberecht P, Said SI and Sreedharan SP *et al.*. (1998) International Union of Pharmacology. XVIII. Nomenclature of receptors for vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide. *Pharmacol Rev* **50**: 265-70 [PMID:9647867]
66. Harmar AJ, Fahrenkrug J, Gozes I, Laburthe M, May V, Pisegna JR, Vaudry D, Vaudry H, Waschek JA and Said SI. (2012) Pharmacology and functions of receptors for vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide: IUPHAR review 1. *Br J Pharmacol* **166**: 4-17 [PMID:22289055]
67. Harmar AJ, Marston HM, Shen S, Spratt C, West KM, Sheward WJ, Morrison CF, Dorin JR, Piggins HD and Reubi JC *et al.*. (2002) The VPAC(2) receptor is essential for circadian function in the mouse suprachiasmatic nuclei. *Cell* **109**: 497-508 [PMID:12086606]
68. Harmar AJ, Sheward WJ, Morrison CF, Waser B, Gugger M and Reubi JC. (2004) Distribution of the

- VPAC2 receptor in peripheral tissues of the mouse. *Endocrinology* **145**: 1203-10 [PMID:14617572]
69. Hashimoto H, Nishino A, Shintani N, Hagihara N, Copeland NG, Jenkins NA, Yamamoto K, Matsuda T, Ishihara T and Nagata S *et al.* (1999) Genomic organization and chromosomal location of the mouse vasoactive intestinal polypeptide 1 (VPAC1) receptor. *Genomics* **58**: 90-3 [PMID:10331949]
 70. Hashimoto H, Nogi H, Mori K, Ohishi H, Shigemoto R, Yamamoto K, Matsuda T, Mizuno N, Nagata S and Baba A. (1996) Distribution of the mRNA for a pituitary adenylate cyclase-activating polypeptide receptor in the rat brain: an in situ hybridization study. *J Comp Neurol* **371**: 567-77 [PMID:8841910]
 71. Hashimoto H, Yamamoto K, Hagigara N, Ogawa N, Nishino A, Aino H, Nogi H, Imanishi K, Matsuda T and Baba A. (1996) cDNA cloning of a mouse pituitary adenylate cyclase-activating polypeptide receptor. *Biochim Biophys Acta* **1281**: 129-33 [PMID:8664310]
 72. Hauk V, Fraccaroli L, Grasso E, Eimon A, Ramhorst R, Hubscher O and Pérez Leirós C. (2014) Monocytes from Sjögren's syndrome patients display increased vasoactive intestinal peptide receptor 2 expression and impaired apoptotic cell phagocytosis. *Clin Exp Immunol* **177**: 662-70 [PMID:24827637]
 73. Hawke Z, Ivanov TR, Bechtold DA, Dhillon H, Lowell BB and Luckman SM. (2009) PACAP neurons in the hypothalamic ventromedial nucleus are targets of central leptin signaling. *J Neurosci* **29**: 14828-35 [PMID:19940178]
 74. Hoffmann J, Miller S, Martins-Oliveira M, Akerman S, Suprongsinchai W, Sun H, Shi L, Wang J, Zhu D and Lehto S *et al.* (2020) PAC1 receptor blockade reduces central nociceptive activity: new approach for primary headache? *Pain* **161**: 1670-1681 [PMID:32142016]
 75. Hughes AT, Fahey B, Cutler DJ, Coogan AN and Piggins HD. (2004) Aberrant gating of photic input to the suprachiasmatic circadian pacemaker of mice lacking the VPAC2 receptor. *J Neurosci* **24**: 3522-6 [PMID:15071099]
 76. Ichikawa S, Goto Y, Uchino S, Kaltreider HB, Goetzl EJ and Sreedharan SP. (1996) Changes in adhesion molecule expression during distinct patterns of immune cell migration in the inflamed lung. *Arch Histol Cytol* **59**: 443-52 [PMID:9037381]
 77. Ichikawa S, Sreedharan SP, Owen RL and Goetzl EJ. (1995) Immunohistochemical localization of type I VIP receptor and NK-1-type substance P receptor in rat lung. *Am J Physiol* **268**: L584-8 [PMID:7537460]
 78. Inagaki N, Yoshida H, Mizuta M, Mizuno N, Fujii Y, Gono T, Miyazaki J and Seino S. (1994) Cloning and functional characterization of a third pituitary adenylate cyclase-activating polypeptide receptor subtype expressed in insulin-secreting cells. *Proc Natl Acad Sci USA* **91**: 2679-83 [PMID:8146174]
 79. Ishihara T, Shigemoto R, Mori K, Takahashi K and Nagata S. (1992) Functional expression and tissue distribution of a novel receptor for vasoactive intestinal polypeptide. *Neuron* **8**: 811-819 [PMID:1314625]
 80. Itoh N, Obata K, Yanaihara N and Okamoto H. (1983) Human preprovasoactive intestinal polypeptide contains a novel PHI-27-like peptide, PHM-27. *Nature* **304**: 547-9 [PMID:6571696]
 81. Jamen F, Persson K, Bertrand G, Rodriguez-Henche N, Puech R, Bockaert J, Ahrén B and Brabet P. (2000) PAC1 receptor-deficient mice display impaired insulinotropic response to glucose and reduced glucose tolerance. *J Clin Invest* **105**: 1307-15 [PMID:10792006]
 82. Jongsma H, Danielsen N, Sundler F and Kanje M. (2000) Alteration of PACAP distribution and PACAP receptor binding in the rat sensory nervous system following sciatic nerve transection. *Brain Res* **853**: 186-196 [PMID:10640616]
 83. Jongsma H, Pettersson LM, Zhang Yz, Reimer MK, Kanje M, Waldenström A, Sundler F and Danielsen N. (2001) Markedly reduced chronic nociceptive response in mice lacking the PAC1 receptor. *Neuroreport* **12**: 2215-9 [PMID:11447337]
 84. Journot L, Waeber C, Pantaloni C, Holsboer F, Seeburg PH, Bockaert J and Spengler D. (1995) Differential signal transduction by six splice variants of the pituitary adenylate cyclase-activating peptide (PACAP) receptor. *Biochem Soc Trans* **23**: 133-137 [PMID:7758697]
 85. Juarranz MG, Santiago B, Torroba M, Gutierrez-Cañas I, Palao G, Galindo M, Abad C, Martinez C, Leceta J and Pablos JL *et al.* (2004) Vasoactive intestinal peptide modulates proinflammatory mediator synthesis in osteoarthritic and rheumatoid synovial cells. *Rheumatology (Oxford)* **43**: 416-22 [PMID:14657510]
 86. Juarranz MG, Van Rampelbergh J, Gourlet P, De Neef P, Cnudde J, Robberecht P and Waelbroeck M. (1999) Different vasoactive intestinal polypeptide receptor domains are involved in the selective recognition of two VPAC(2)-selective ligands. *Mol Pharmacol* **56**: 1280-7 [PMID:10570056]
 87. Kaltreider HB, Ichikawa S, Byrd PK, Ingram DA, Kishiyama JL, Sreedharan SP, Warnock ML, Beck JM

- and Goetzl EJ. (1997) Upregulation of neuropeptides and neuropeptide receptors in a murine model of immune inflammation in lung parenchyma. *Am J Respir Cell Mol Biol* **16**: 133-44 [PMID:9032120]
88. Kawaguchi C, Tanaka K, Isojima Y, Shintani N, Hashimoto H, Baba A and Nagai K. (2003) Changes in light-induced phase shift of circadian rhythm in mice lacking PACAP. *Biochem Biophys Res Commun* **310**: 169-75 [PMID:14511666]
 89. Kienlen Campard P, Crochemore C, René F, Monnier D, Koch B and Loeffler JP. (1997) PACAP type I receptor activation promotes cerebellar neuron survival through the cAMP/PKA signaling pathway. *DNA Cell Biol* **16**: 323-33 [PMID:9115641]
 90. Kojima M, Ito T, Oono T, Hisano T, Igarashi H, Arita Y, Kawabe K, Coy DH, Jensen RT and Nawata H. (2005) VIP attenuation of the severity of experimental pancreatitis is due to VPAC1 receptor-mediated inhibition of cytokine production. *Pancreas* **30**: 62-70 [PMID:15632701]
 91. Krempels K, Usdin TB, Harta G and Mezey E. (1995) PACAP acts through VIP type 2 receptors in the rat testis. *Neuropeptides* **29**: 315-20 [PMID:8837957]
 92. Kumar S, Pioszak A, Zhang C, Swaminathan K and Xu HE. (2011) Crystal Structure of the PAC1R Extracellular Domain Unifies a Consensus Fold for Hormone Recognition by Class B G-Protein Coupled Receptors. *PLoS ONE* **6**: e19682 [PMID:21625560]
 93. Laburthe M, Amiranoff B, Boige N, Rouyer-Fessard C, Tatemoto K and Moroder L. (1983) Interaction of GRF with VIP receptors and stimulation of adenylate cyclase in rat and human intestinal epithelial membranes. Comparison with PHI and secretin. *FEBS Lett* **159**: 89-92 [PMID:6307754]
 94. Laburthe M and Couvineau A. (2002) Molecular pharmacology and structure of VPAC Receptors for VIP and PACAP. *Regul Pept* **108**: 165-73 [PMID:12220741]
 95. Laburthe M, Couvineau A and Marie JC. (2002) VPAC receptors for VIP and PACAP. *Recept Channels* **8**: 137-53 [PMID:12529932]
 96. Laburthe M, Couvineau A and Tan V. (2007) Class II G protein-coupled receptors for VIP and PACAP: structure, models of activation and pharmacology. *Peptides* **28**: 1631-9 [PMID:17574305]
 97. Laburthe M, Rousset M, Boissard C, Chevalier G, Zweibaum A and Rosselin G. (1978) Vasoactive intestinal peptide: a potent stimulator of adenosine 3':5'-cyclic monophosphate accumulation in gut carcinoma cell lines in culture. *Proc Natl Acad Sci USA* **75**: 2772-5 [PMID:208077]
 98. Lang B, Song B, Davidson W, MacKenzie A, Smith N, McCaig CD, Harmar AJ and Shen S. (2006) Expression of the human PAC1 receptor leads to dose-dependent hydrocephalus-related abnormalities in mice. *J Clin Invest* **116**: 1924-34 [PMID:16823490]
 99. Lelièvre V, Pineau N, Du J, Wen CH, Nguyen T, Janet T, Muller JM and Waschek JA. (1998) Differential effects of peptide histidine isoleucine (PHI) and related peptides on stimulation and suppression of neuroblastoma cell proliferation. A novel VIP-independent action of PHI via MAP kinase. *J Biol Chem* **273**: 19685-90 [PMID:9677397]
 100. Levinson DF, Duan J, Oh S, Wang K, Sanders AR, Shi J, Zhang N, Mowry BJ, Olincy A and Amin F *et al.* (2011) Copy number variants in schizophrenia: confirmation of five previous findings and new evidence for 3q29 microdeletions and VIPR2 duplications. *Am J Psychiatry* **168**: 302-16 [PMID:21285140]
 101. Luis J and Said SI. (1990) Characterization of VIP- and helodermin-preferring receptors on human small cell lung carcinoma cell lines. *Peptides* **11**: 1239-44 [PMID:1965034]
 102. Lutz EM, Sheward WJ, West KM, Morrow JA, Fink G and Harmar AJ. (1993) The VIP2 receptor: molecular characterisation of a cDNA encoding a novel receptor for vasoactive intestinal peptide. *FEBS Lett* **334**: 3-8 [PMID:8224221]
 103. Mabuchi T, Shintani N, Matsumura S, Okuda-Ashitaka E, Hashimoto H, Muratani T, Minami T, Baba A and Ito S. (2004) Pituitary adenylate cyclase-activating polypeptide is required for the development of spinal sensitization and induction of neuropathic pain. *J Neurosci* **24**: 7283-91 [PMID:15317855]
 104. Mackay M, Fantes J, Scherer S, Boyle S, West K, Tsui LC, Belloni E, Lutz E, Van Heyningen V and Harmar AJ. (1996) Chromosomal localization in mouse and human of the vasoactive intestinal peptide receptor type 2 gene: a possible contributor to the holoprosencephaly 3 phenotype. *Genomics* **37**: 345-53 [PMID:8938447]
 105. MacKenzie CJ, Lutz EM, Johnson MS, Robertson DN, Holland PJ and Mitchell R. (2001) Mechanisms of phospholipase C activation by the vasoactive intestinal polypeptide/pituitary adenylate cyclase-activating polypeptide type 2 receptor. *Endocrinology* **142**: 1209-17 [PMID:11181537]
 106. MacKenzie CJ, Lutz EM, McCulloch DA, Mitchell R and Harmar AJ. (1996) Phospholipase C activation by VIP1 and VIP2 receptors expressed in COS 7 cells involves a pertussis toxin-sensitive mechanism. *Ann N*

- Y Acad Sci* **805**: 579-84 [PMID:8993443]
107. Malhotra RK, Wakade TD and Wakade AR. (1988) Vasoactive intestinal polypeptide and muscarine mobilize intracellular Ca²⁺ through breakdown of phosphoinositides to induce catecholamine secretion. Role of IP₃ in exocytosis. *J Biol Chem* **263**: 2123-6 [PMID:3123488]
 108. Martin JL, Dietl MM, Hof PR, Palacios JM and Magistretti PJ. (1987) Autoradiographic mapping of [mono[125I]iodo-Tyr¹⁰, Met¹⁷]vasoactive intestinal peptide binding sites in the rat brain. *Neuroscience* **23**: 539-65 [PMID:3437978]
 109. Martinez C, Abad C, Delgado M, Arranz A, Juarranz MG, Rodriguez-Henche N, Brabet P, Leceta J and Gomariz RP. (2002) Anti-inflammatory role in septic shock of pituitary adenylate cyclase-activating polypeptide receptor. *Proc Natl Acad Sci USA* **99**: 1053-8 [PMID:11792830]
 110. Matsuyama S, Matsumoto A, Hashimoto H, Shintani N and Baba A. (2003) Impaired long-term potentiation in vivo in the dentate gyrus of pituitary adenylate cyclase-activating polypeptide (PACAP) or PACAP type 1 receptor-mutant mice. *Neuroreport* **14**: 2095-8 [PMID:14600504]
 111. McCulloch DA, Lutz EM, Johnson MS, Robertson DN, MacKenzie CJ, Holland PJ and Mitchell R. (2001) ADP-ribosylation factor-dependent phospholipase D activation by VPAC receptors and a PAC(1) receptor splice variant. *Mol Pharmacol* **59**: 1523-32 [PMID:11353814]
 112. Minami Y, Furuno K, Akiyama M, Moriya T and Shibata S. (2002) Pituitary adenylate cyclase-activating polypeptide produces a phase shift associated with induction of mPer expression in the mouse suprachiasmatic nucleus. *Neuroscience* **113**: 37-45 [PMID:12123682]
 113. Miyata A, Arimura A, Dahl RR, Minamino N, Uehara A, Jiang L, Culler MD and Coy DH. (1989) Isolation of a novel 38 residue-hypothalamic polypeptide which stimulates adenylate cyclase in pituitary cells. *Biochem Biophys Res Commun* **164**: 567-74 [PMID:2803320]
 114. Miyata A, Jiang L, Dahl RD, Kitada C, Kubo K, Fujino M, Minamino N and Arimura A. (1990) Isolation of a neuropeptide corresponding to the N-terminal 27 residues of the pituitary adenylate cyclase activating polypeptide with 38 residues (PACAP₃₈). *Biochem Biophys Res Commun* **170**: 643-8 [PMID:2383262]
 115. Moller K and Sundler F. (1996) Expression of pituitary adenylate cyclase activating peptide (PACAP) and PACAP type I receptors in the rat adrenal medulla. *Regul Pept* **63**: 129-39 [PMID:8837221]
 116. Moody TW, Jensen RT, Fridkin M and Gozes I. (2002) (N-stearyl, norleucine¹⁷)VIPhybrid is a broad spectrum vasoactive intestinal peptide receptor antagonist. *J Mol Neurosci* **18**: 29-35 [PMID:11931347]
 117. Moreno D, Gourlet P, De Neef P, Cnudde J, Waelbroeck M and Robberecht P. (2000) Development of selective agonists and antagonists for the human vasoactive intestinal polypeptide VPAC(2) receptor. *Peptides* **21**: 1543-9 [PMID:11068102]
 118. Moro O and Lerner EA. (1997) Maxadilan, the vasodilator from sand flies, is a specific pituitary adenylate cyclase activating peptide type I receptor agonist. *J Biol Chem* **272**: 966-70 [PMID:8995389]
 119. Moro O, Wakita K, Ohnuma M, Denda S, Lerner EA and Tajima M. (1999) Functional characterization of structural alterations in the sequence of the vasodilatory peptide maxadilan yields a pituitary adenylate cyclase-activating peptide type 1 receptor-specific antagonist. *J Biol Chem* **274**: 23103-10 [PMID:10438479]
 120. Mounien L, Do Rego JC, Bizet P, Boutelet I, Gourcerol G, Fournier A, Brabet P, Costentin J, Vaudry H and Jégou S. (2009) Pituitary adenylate cyclase-activating polypeptide inhibits food intake in mice through activation of the hypothalamic melanocortin system. *Neuropsychopharmacology* **34**: 424-35 [PMID:18536705]
 121. Murthy KS, Zhang KM, Jin JG, Grider JR and Makhlof GM. (1993) VIP-mediated G protein-coupled Ca²⁺ influx activates a constitutive NOS in dispersed gastric muscle cells. *Am J Physiol* **265**: G660-71 [PMID:7694477]
 122. Neumann JM, Couvineau A, Murail S, Lacapère JJ, Jamin N and Laburthe M. (2008) Class-B GPCR activation: is ligand helix-capping the key? *Trends Biochem Sci* **33**: 314-9 [PMID:18555686]
 123. Nicole P, Du K, Couvineau A and Laburthe M. (1998) Site-directed mutagenesis of human vasoactive intestinal peptide receptor subtypes VIP1 and VIP2: evidence for difference in the structure-function relationship. *J Pharmacol Exp Ther* **284**: 744-50 [PMID:9454823]
 124. Nicole P, Lins L, Rouyer-Fessard C, Drouot C, Fulcrand P, Thomas A, Couvineau A, Martinez J, Brasseur R and Laburthe M. (2000) Identification of key residues for interaction of vasoactive intestinal peptide with human VPAC1 and VPAC2 receptors and development of a highly selective VPAC1 receptor agonist. Alanine scanning and molecular modeling of the peptide. *J Biol Chem* **275**: 24003-12

[PMID:10801840]

125. Nielsen HS, Hannibal J and Fahrenkrug J. (1998) Expression of pituitary adenylate cyclase activating polypeptide (PACAP) in the postnatal and adult rat cerebellar cortex. *Neuroreport* **9**: 2639-42
[PMID:9721947]
126. O'Donnell M, Garippa RJ, Rinaldi N, Selig WM, Simko B, Renzetti L, Tannu SA, Wasserman MA, Welton A and Bolin DR. (1994) Ro 25-1553: a novel, long-acting vasoactive intestinal peptide agonist. Part I: In vitro and in vivo bronchodilator studies. *J Pharmacol Exp Ther* **270**: 1282-8 [PMID:7932180]
127. O'Donnell M, Garippa RJ, Rinaldi N, Selig WM, Tocker JE, Tannu SA, Wasserman MA, Welton A and Bolin DR. (1994) Ro 25-1553: a novel, long-acting vasoactive intestinal peptide agonist. Part II: Effect on in vitro and in vivo models of pulmonary anaphylaxis. *J Pharmacol Exp Ther* **270**: 1289-94
[PMID:7932181]
128. Ogi K, Miyamoto Y, Masuda Y, Habata Y, Hosoya M, Ohtaki T, Masuo Y, Onda H and Fujino M. (1993) Molecular cloning and functional expression of a cDNA encoding a human pituitary adenylate cyclase activating polypeptide receptor. *Biochem Biophys Res Commun* **196**: 1511-21 [PMID:7902709]
129. Ottaway CA. (1987) Selective effects of vasoactive intestinal peptide on the mitogenic response of murine T cells. *Immunology* **62**: 291-7 [PMID:2960611]
130. Otto C, Hein L, Brede M, Jahns R, Engelhardt S, Gröne HJ and Schütz G. (2004) Pulmonary hypertension and right heart failure in pituitary adenylate cyclase-activating polypeptide type I receptor-deficient mice. *Circulation* **110**: 3245-51 [PMID:15520307]
131. Otto C, Kovalchuk Y, Wolfer DP, Gass P, Martin M, Zuschratter W, Gröne HJ, Kellendonk C, Tronche F and Maldonado R *et al.* (2001) Impairment of mossy fiber long-term potentiation and associative learning in pituitary adenylate cyclase activating polypeptide type I receptor-deficient mice. *J Neurosci* **21**: 5520-7 [PMID:11466423]
132. Otto C, Martin M, Wolfer DP, Lipp HP, Maldonado R and Schütz G. (2001) Altered emotional behavior in PACAP-type-I-receptor-deficient mice. *Brain Res Mol Brain Res* **92**: 78-84 [PMID:11483244]
133. Pantaloni C, Brabet P, Bilanges B, Dumuis A, Houssami S, Spengler D, Bockaert J and Journot L. (1996) Alternative splicing in the N-terminal extracellular domain of the pituitary adenylate cyclase-activating polypeptide (PACAP) receptor modulates receptor selectivity and relative potencies of PACAP-27 and PACAP-38 in phospholipase C activation. *J Biol Chem* **271**: 22146-51 [PMID:8703026]
134. Pereira P, Reddy VB, Kouniga K, Bello Y and Lerner E. (2002) Maxadilan activates PAC1 receptors expressed in *Xenopus laevis* xelanophores. *Pigment Cell Res* **15**: 461-6 [PMID:12453189]
135. Persson K and Ahrén B. (2002) The neuropeptide PACAP contributes to the glucagon response to insulin-induced hypoglycaemia in mice. *Acta Physiol Scand* **175**: 25-8 [PMID:11982501]
136. Piggins HD. (2011) Schizophrenia: Zooming in on a gene. *Nature* **471**: 455-6 [PMID:21430769]
137. Pilzer I and Gozes I. (2006) A splice variant to PACAP receptor that is involved in spermatogenesis is expressed in astrocytes. *Ann N Y Acad Sci* **1070**: 484-90 [PMID:16888214]
138. Pisegna JR, Lyu RM and Germano PM. (2000) Essential structural motif in the C-terminus of the PACAP type I receptor for signal transduction and internalization. *Ann N Y Acad Sci* **921**: 195-201
[PMID:11193823]
139. Pisegna JR and Wank SA. (1993) Molecular cloning and functional expression of the pituitary adenylate cyclase-activating polypeptide type I receptor. *Proc Natl Acad Sci USA* **90**: 6345-9 [PMID:8392197]
140. Pisegna JR and Wank SA. (1996) Cloning and characterization of the signal transduction of four splice variants of the human pituitary adenylate cyclase activating polypeptide receptor. Evidence for dual coupling to adenylate cyclase and phospholipase C. *J Biol Chem* **271**: 17267-74 [PMID:8663363]
141. Pozo D. (2003) VIP- and PACAP-mediated immunomodulation as prospective therapeutic tools. *Trends Mol Med* **9**: 211-7 [PMID:12763526]
142. Przywara DA, Guo X, Angelilli ML, Wakade TD and Wakade AR. (1996) A non-cholinergic transmitter, pituitary adenylate cyclase-activating polypeptide, utilizes a novel mechanism to evoke catecholamine secretion in rat adrenal chromaffin cells. *J Biol Chem* **271**: 10545-50 [PMID:8631854]
143. Rangon CM, Goursaud S, Medja F, Lelièvre V, Mounien L, Husson I, Brabet P, Jégou S, Janet T and Gressens P. (2005) VPAC2 receptors mediate vasoactive intestinal peptide-induced neuroprotection against neonatal excitotoxic brain lesions in mice. *J Pharmacol Exp Ther* **314**: 745-52 [PMID:15872042]
144. Rawlings SR and Hezareh M. (1996) Pituitary adenylate cyclase-activating polypeptide (PACAP) and PACAP/vasoactive intestinal polypeptide receptors: actions on the anterior pituitary gland. *Endocr Rev* **17**: 4-29 [PMID:8641222]

145. Reglodi D, Somogyvari-Vigh A, Vigh S, Kozicz T and Arimura A. (2000) Delayed systemic administration of PACAP38 is neuroprotective in transient middle cerebral artery occlusion in the rat. *Stroke* **31**: 1411-7 [PMID:10835464]
146. Reichlin S. (1988) Neuroendocrine significance of vasoactive intestinal polypeptide. *Ann N Y Acad Sci* **527**: 431-49 [PMID:2898911]
147. Ressler KJ, Mercer KB, Bradley B, Jovanovic T, Mahan A, Kerley K, Norrholm SD, Kilaru V, Smith AK and Myers AJ *et al.* (2011) Post-traumatic stress disorder is associated with PACAP and the PAC1 receptor. *Nature* **470**: 492-7 [PMID:21350482]
148. Reubi JC. (2000) In vitro evaluation of VIP/PACAP receptors in healthy and diseased human tissues. Clinical implications. *Ann N Y Acad Sci* **921**: 1-25 [PMID:11193811]
149. Reubi JC, Läderach U, Waser B, Gebbers JO, Robberecht P and Laissue JA. (2000) Vasoactive intestinal peptide/pituitary adenylate cyclase-activating peptide receptor subtypes in human tumors and their tissues of origin. *Cancer Res* **60**: 3105-12 [PMID:10850463]
150. Robberecht P, De Neef P and Lefebvre RA. (1998) Influence of selective VIP receptor agonists in the rat gastric fundus. *Eur J Pharmacol* **359**: 77-80 [PMID:9831296]
151. Robberecht P, Gourlet P, De Neef P, Woussen-Colle MC, Vandermeers-Piret MC, Vandermeers A and Christophe J. (1992) Structural requirements for the occupancy of pituitary adenylate-cyclase-activating-peptide (PACAP) receptors and adenylate cyclase activation in human neuroblastoma NB-OK-1 cell membranes. Discovery of PACAP(6-38) as a potent antagonist. *Eur J Biochem* **207**: 239-46 [PMID:1321043]
152. Robberecht P, Waelbroeck M, De Neef P, Tastenoy M, Gourlet P, Cogniaux J and Christophe J. (1988) A new type of functional VIP receptor has an affinity for helodermin in human SUP-T1 lymphoblasts. *FEBS Lett* **228**: 351-5 [PMID:2830146]
153. Robberecht P, Woussen-Colle MC, De Neef P, Gourlet P, Buscail L, Vandermeers A, Vandermeers-Piret MC and Christophe J. (1991) The two forms of the pituitary adenylate cyclase activating polypeptide (PACAP (1-27) and PACAP (1-38)) interact with distinct receptors on rat pancreatic AR 4-2J cell membranes. *FEBS Lett* **286**: 133-6 [PMID:1650711]
154. Rubio-Beltrán E, Correnti E, Deen M, Kamm K, Kelderman T, Papetti L, Vigneri S, MaassenVanDenBrink A, Edvinsson L and European Headache Federation School of Advanced Studies (EHF-SAS). (2018) PACAP38 and PAC₁ receptor blockade: a new target for headache? *J Headache Pain* **19**: 64 [PMID:30088106]
155. Said SI. (1996) Vasoactive intestinal peptide and nitric oxide: divergent roles in relation to tissue injury. *Ann N Y Acad Sci* **805**: 379-87; discussion 387-8 [PMID:8993418]
156. Said SI. (1991) Vasoactive intestinal polypeptide: biologic role in health and disease. *Trends Endocrinol Metab* **2**: 107-12 [PMID:18411175]
157. Said SI and Mutt V. (1970) Polypeptide with broad biological activity: isolation from small intestine. *Science* **169**: 1217-8 [PMID:5450698]
158. Said SI and Mutt V. (1972) Isolation from porcine-intestinal wall of a vasoactive octacosapeptide related to secretin and to glucagon. *Eur J Biochem* **28**: 199-204 [PMID:5069712]
159. Said SI and Rattan S. (2004) The multiple mediators of neurogenic smooth muscle relaxation. *Trends Endocrinol Metab* **15**: 189-91 [PMID:15223046]
160. Shen S, Spratt C, Sheward WJ, Kallo I, West K, Morrison CF, Coen CW, Marston HM and Harmar AJ. (2000) Overexpression of the human VPAC2 receptor in the suprachiasmatic nucleus alters the circadian phenotype of mice. *Proc Natl Acad Sci USA* **97**: 11575-80 [PMID:11027354]
161. Sheward WJ, Lutz EM, Copp AJ and Harmar AJ. (1998) Expression of PACAP, and PACAP type 1 (PAC1) receptor mRNA during development of the mouse embryo. *Brain Res Dev Brain Res* **109**: 245-53 [PMID:9729410]
162. Sheward WJ, Lutz EM and Harmar AJ. (1995) The distribution of vasoactive intestinal peptide₂ receptor messenger RNA in the rat brain and pituitary gland as assessed by in situ hybridization. *Neuroscience* **67**: 409-18 [PMID:7675176]
163. Sheward WJ, Naylor E, Knowles-Barley S, Armstrong JD, Brooker GA, Seckl JR, Turek FW, Holmes MC, Zee PC and Harmar AJ. (2010) Circadian control of mouse heart rate and blood pressure by the suprachiasmatic nuclei: behavioral effects are more significant than direct outputs. *PLoS ONE* **5**: e9783 [PMID:20339544]
164. Shioda S, Shuto Y, Somogyvari-Vigh A, Legradi G, Onda H, Coy DH, Nakajo S and Arimura A. (1997)

- Localization and gene expression of the receptor for pituitary adenylate cyclase-activating polypeptide in the rat brain. *Neurosci Res* **28**: 345-54 [PMID:9274830]
165. Shivers BD, Göröcs TJ, Gottschall PE and Arimura A. (1991) Two high affinity binding sites for pituitary adenylate cyclase-activating polypeptide have different tissue distributions. *Endocrinology* **128**: 3055-65 [PMID:2036976]
 166. Sorg O and Magistretti PJ. (1992) Vasoactive intestinal peptide and noradrenaline exert long-term control on glycogen levels in astrocytes: blockade by protein synthesis inhibition. *J Neurosci* **12**: 4923-31 [PMID:1334506]
 167. Spengler D, Waeber C, Pantaloni C, Holsboer F, Bockaert J, Seeburg PH and Journot L. (1993) Differential signal transduction by five splice variants of the PACAP receptor. *Nature* **365**: 170-5 [PMID:8396727]
 168. Sreedharan SP, Huang JX, Cheung MC and Goetzl EJ. (1995) Structure, expression, and chromosomal localization of the type I human vasoactive intestinal peptide receptor gene. *Proc Natl Acad Sci USA* **92**: 2939-43 [PMID:7708752]
 169. Sreedharan SP, Patel DR, Huang JX and Goetzl EJ. (1993) Cloning and functional expression of a human neuroendocrine vasoactive intestinal peptide receptor. *Biochem Biophys Res Commun* **193**: 546-553 [PMID:8390245]
 170. Sreedharan SP, Patel DR, Xia M, Ichikawa S and Goetzl EJ. (1994) Human vasoactive intestinal peptide1 receptors expressed by stable transfectants couple to two distinct signaling pathways. *Biochem Biophys Res Commun* **203**: 141-8 [PMID:8074647]
 171. Stoffel M, Espinosa 3rd R, Trabb JB, Le Beau MM and Bell GI. (1994) Human type I pituitary adenylate cyclase activating polypeptide receptor (ADCYAP1R): localization to chromosome band 7p14 and integration into the cytogenetic, physical, and genetic map of chromosome 7. *Genomics* **23**: 697-9 [PMID:7851900]
 172. Stroth N and Eiden LE. (2010) Stress hormone synthesis in mouse hypothalamus and adrenal gland triggered by restraint is dependent on pituitary adenylate cyclase-activating polypeptide signaling. *Neuroscience* **165**: 1025-30 [PMID:19931358]
 173. Sun C, Song D, Davis-Taber RA, Barrett LW, Scott VE, Richardson PL, Pereda-Lopez A, Uchic ME, Solomon LR and Lake MR *et al.*. (2007) Solution structure and mutational analysis of pituitary adenylate cyclase-activating polypeptide binding to the extracellular domain of PAC1-RS. *Proc Natl Acad Sci USA* **104**: 7875-80 [PMID:17470806]
 174. Sundler F. (1999) Preliminary observations of phenotypic alterations in the PAC1 receptor knockout mouse. *Soc Neurosci Abstracts* **25**: 441-441
 175. Svoboda M, Tastenoy M, Van Rampelbergh J, Goossens JF, De Neef P, Waelbroeck M and Robberecht P. (1994) Molecular cloning and functional characterization of a human VIP receptor from SUP-T1 lymphoblasts. *Biochem Biophys Res Commun* **205**: 1617-24 [PMID:7811244]
 176. Tan YV, Abad C, Lopez R, Dong H, Liu S, Lee A, Gomariz RP, Leceta J and Waschek JA. (2009) Pituitary adenylate cyclase-activating polypeptide is an intrinsic regulator of Treg abundance and protects against experimental autoimmune encephalomyelitis. *Proc Natl Acad Sci USA* **106**: 2012-7 [PMID:19190179]
 177. Tan YV, Couvineau A, Murail S, Ceraudo E, Neumann JM, Lacapère JJ and Laburthe M. (2006) Peptide agonist docking in the N-terminal ectodomain of a class II G protein-coupled receptor, the VPAC1 receptor. Photoaffinity, NMR, and molecular modeling. *J Biol Chem* **281**: 12792-8 [PMID:16520374]
 178. Tatemoto K and Mutt V. (1981) Isolation and characterization of the intestinal peptide porcine PHI (PHI-27), a new member of the glucagon-secretin family. *Proc Natl Acad Sci USA* **78**: 6603-7 [PMID:6947244]
 179. Tomimoto S, Hashimoto H, Shintani N, Yamamoto K, Kawabata Y, Hamagami K, Yamagata K, Miyagawa J and Baba A. (2004) Overexpression of pituitary adenylate cyclase-activating polypeptide in islets inhibits hyperinsulinemia and islet hyperplasia in agouti yellow mice. *J Pharmacol Exp Ther* **309**: 796-803 [PMID:14742740]
 180. Tse DL, Pang RT, Wong AO, Chan SM, Vaudry H and Chow BK. (2002) Identification of a potential receptor for both peptide histidine isoleucine and peptide histidine valine. *Endocrinology* **143**: 1327-36 [PMID:11897689]
 181. Tsukiyama N, Saida Y, Kakuda M, Shintani N, Hayata A, Morita Y, Tanida M, Tajiri M, Hazama K and Ogata K *et al.*. (2011) PACAP centrally mediates emotional stress-induced corticosterone responses in mice. *Stress* **14**: 368-75 [PMID:21438773]
 182. Tsutsumi M, Claus TH, Liang Y, Li Y, Yang L, Zhu J, Dela Cruz F, Peng X, Chen H and Yung SL *et al.*

- (2002) A potent and highly selective VPAC2 agonist enhances glucose-induced insulin release and glucose disposal: a potential therapy for type 2 diabetes. *Diabetes* **51**: 1453-60 [PMID:11978642]
183. Uchida D, Tatsuno I, Tanaka T, Hirai A, Saito Y, Moro O and Tajima M. (1998) Maxadilan is a specific agonist and its deleted peptide (M65) is a specific antagonist for PACAP type 1 receptor. *Ann N Y Acad Sci* **865**: 253-8 [PMID:9928019]
184. Usdin TB, Bonner TI and Mezey E. (1994) Two receptors for vasoactive intestinal polypeptide with similar specificity and complementary distributions. *Endocrinology* **135**: 2662-80 [PMID:7988457]
185. Vacic V, McCarthy S, Malhotra D, Murray F, Chou HH, Peoples A, Makarov V, Yoon S, Bhandari A and Corominas R *et al.* (2011) Duplications of the neuropeptide receptor gene VIPR2 confer significant risk for schizophrenia. *Nature* **471**: 499-503 [PMID:21346763]
186. Van Rampelbergh J, Gourlet P, De Neef P, Robberecht P and Waelbroeck M. (1996) Properties of the pituitary adenylate cyclase-activating polypeptide I and II receptors, vasoactive intestinal peptide1, and chimeric amino-terminal pituitary adenylate cyclase-activating polypeptide/vasoactive intestinal peptide1 receptors: evidence for multiple receptor states. *Mol Pharmacol* **50**: 1596-604 [PMID:8967982]
187. Van Rampelbergh J, Poloczek P, François I, Delporte C, Winand J, Robberecht P and Waelbroeck M. (1997) The pituitary adenylate cyclase activating polypeptide (PACAP I) and VIP (PACAP II VIP1) receptors stimulate inositol phosphate synthesis in transfected CHO cells through interaction with different G proteins. *Biochim Biophys Acta* **1357**: 249-55 [PMID:9223629]
188. Vaudry D, Falluel-Morel A, Basille M, Pamantung TF, Fontaine M, Fournier A, Vaudry H and Gonzalez BJ. (2003) Pituitary adenylate cyclase-activating polypeptide prevents C2-ceramide-induced apoptosis of cerebellar granule cells. *J Neurosci Res* **72**: 303-16 [PMID:12692897]
189. Vaudry D, Gonzalez BJ, Basille M, Anouar Y, Fournier A and Vaudry H. (1998) Pituitary adenylate cyclase-activating polypeptide stimulates both c-fos gene expression and cell survival in rat cerebellar granule neurons through activation of the protein kinase A pathway. *Neuroscience* **84**: 801-12 [PMID:9579785]
190. Vaudry D, Gonzalez BJ, Basille M, Fournier A and Vaudry H. (1999) Neurotrophic activity of pituitary adenylate cyclase-activating polypeptide on rat cerebellar cortex during development. *Proc Natl Acad Sci USA* **96**: 9415-20 [PMID:10430957]
191. Vaudry D, Gonzalez BJ, Basille M, Pamantung TF, Fontaine M, Fournier A and Vaudry H. (2000) The neuroprotective effect of pituitary adenylate cyclase-activating polypeptide on cerebellar granule cells is mediated through inhibition of the CED3-related cysteine protease caspase-3/CPP32. *Proc Natl Acad Sci USA* **97**: 13390-5 [PMID:11087878]
192. Vaudry D, Gonzalez BJ, Basille M, Yon L, Fournier A and Vaudry H. (2000) Pituitary adenylate cyclase-activating polypeptide and its receptors: from structure to functions. *Pharmacol Rev* **52**: 269-324 [PMID:10835102]
193. Vaudry D, Pamantung TF, Basille M, Rousselle C, Fournier A, Vaudry H, Beauvillain JC and Gonzalez BJ. (2002) PACAP protects cerebellar granule neurons against oxidative stress-induced apoptosis. *Eur J Neurosci* **15**: 1451-60 [PMID:12028355]
194. Vaudry D, Rousselle C, Basille M, Falluel-Morel A, Pamantung TF, Fontaine M, Fournier A, Vaudry H and Gonzalez BJ. (2002) Pituitary adenylate cyclase-activating polypeptide protects rat cerebellar granule neurons against ethanol-induced apoptotic cell death. *Proc Natl Acad Sci USA* **99**: 6398-403 [PMID:11972030]
195. Vertongen P, Schiffmann SN, Gourlet P and Robberecht P. (1997) Autoradiographic visualization of the receptor subclasses for vasoactive intestinal polypeptide (VIP) in rat brain. *Peptides* **18**: 1547-1554 [PMID:9437715]
196. Villalba M, Bockaert J and Journot L. (1997) Pituitary adenylate cyclase-activating polypeptide (PACAP-38) protects cerebellar granule neurons from apoptosis by activating the mitogen-activated protein kinase (MAP kinase) pathway. *J Neurosci* **17**: 83-90 [PMID:8987738]
197. Voice JK, Dorsam G, Chan RC, Grininger C, Kong Y and Goetzl EJ. (2002) Immunoefector and immunoregulatory activities of vasoactive intestinal peptide. *Regul Pept* **109**: 199-208 [PMID:12409234]
198. Voice JK, Dorsam G, Lee H, Kong Y and Goetzl EJ. (2001) Allergic diathesis in transgenic mice with constitutive T cell expression of inducible vasoactive intestinal peptide receptor. *FASEB J* **15**: 2489-96 [PMID:11689474]
199. Voice JK, Grininger C, Kong Y, Bangale Y, Paul S and Goetzl EJ. (2003) Roles of vasoactive intestinal peptide (VIP) in the expression of different immune phenotypes by wild-type mice and T cell-targeted

- type II VIP receptor transgenic mice. *J Immunol* **170**: 308-14 [PMID:12496414]
200. Waschek JA, Casillas RA, Nguyen TB, DiCicco-Bloom EM, Carpenter EM and Rodriguez WI. (1998) Neural tube expression of pituitary adenylate cyclase-activating peptide (PACAP) and receptor: potential role in patterning and neurogenesis. *Proc Natl Acad Sci USA* **95**: 9602-7 [PMID:9689127]
201. Wei Y and Mojsov S. (1996) Tissue specific expression of different human receptor types for pituitary adenylate cyclase activating polypeptide and vasoactive intestinal polypeptide: implications for their role in human physiology. *J Neuroendocrinol* **8**: 811-7 [PMID:8933357]
202. Xia M, Sreedharan SP, Bolin DR, Gaufo GO and Goetzl EJ. (1997) Novel cyclic peptide agonist of high potency and selectivity for the type II vasoactive intestinal peptide receptor. *J Pharmacol Exp Ther* **281**: 629-33 [PMID:9152366]
203. Xiong Y, Guo J, Candelore MR, Liang R, Miller C, Dallas-Yang Q, Jiang G, McCann PE, Qureshi SA and Tong X *et al.*. (2012) Discovery of a novel glucagon receptor antagonist N-[(4-[(1S)-1-[3-(3, 5-dichlorophenyl)-5-(6-methoxynaphthalen-2-yl)-1H-pyrazol-1-yl]ethyl]phenyl)carbonyl]- β -alanine (MK-0893) for the treatment of type II diabetes. *J Med Chem* **55**: 6137-48 [PMID:22708876]
204. Yada T, Sakurada M, Ihida K, Nakata M, Murata F, Arimura A and Kikuchi M. (1994) Pituitary adenylate cyclase activating polypeptide is an extraordinarily potent intra-pancreatic regulator of insulin secretion from islet beta-cells. *J Biol Chem* **269**: 1290-1293 [PMID:8288592]
205. Yadav M, Huang MC and Goetzl EJ. (2011) VPAC1 (vasoactive intestinal peptide (VIP) receptor type 1) G protein-coupled receptor mediation of VIP enhancement of murine experimental colitis. *Cell Immunol* **267**: 124-32 [PMID:21295288]
206. Yamamoto K, Hashimoto H, Tomimoto S, Shintani N, Miyazaki J, Tashiro F, Aihara H, Nammo T, Li M and Yamagata K *et al.*. (2003) Overexpression of PACAP in transgenic mouse pancreatic beta-cells enhances insulin secretion and ameliorates streptozotocin-induced diabetes. *Diabetes* **52**: 1155-62 [PMID:12716746]
207. Yiangou Y, Di Marzo V, Spokes RA, Panico M, Morris HR and Bloom SR. (1987) Isolation, characterization, and pharmacological actions of peptide histidine valine 42, a novel prepro-vasoactive intestinal peptide-derived peptide. *J Biol Chem* **262**: 14010-14013 [PMID:3654650]
208. Yon L, Breault L, Contesse V, Bellancourt G, Delarue C, Fournier A, Lehoux JG, Vaudry H and Gallo-Payet N. (1998) Localization, characterization, and second messenger coupling of pituitary adenylate cyclase-activating polypeptide receptors in the fetal human adrenal gland during the second trimester of gestation. *J Clin Endocrinol Metab* **83**: 1299-305 [PMID:9543159]
209. Zaben M, Sheward WJ, Shtaya A, Abbosh C, Harmar AJ, Pringle AK and Gray WP. (2009) The neurotransmitter VIP expands the pool of symmetrically dividing postnatal dentate gyrus precursors via VPAC2 receptors or directs them toward a neuronal fate via VPAC1 receptors. *Stem Cells* **27**: 2539-51 [PMID:19650041]
210. Zhou CJ, Shioda S, Shibanuma M, Nakajo S, Funahashi H, Nakai Y, Arimura A and Kikuyama S. (1999) Pituitary adenylate cyclase-activating polypeptide receptors during development: expression in the rat embryo at primitive streak stage. *Neuroscience* **93**: 375-91 [PMID:10430501]
211. Zupan V, Hill JM, Brenneman DE, Gozes I, Fridkin M, Robberecht P, Evrard P and Gressens P. (1998) Involvement of pituitary adenylate cyclase-activating polypeptide II vasoactive intestinal peptide 2 receptor in mouse neocortical astrocytogenesis. *J Neurochem* **70**: 2165-73 [PMID:9572304]